PathologyMD Anderson Residual Cancer Burden Index
Primary Tumor Bed
mm
mm
%
Area of tumor bed with invasive cancer
Lymph Node Status
count
Number of involved nodes
mm
Diameter of largest nodal met
Awaiting Data
Please enter tumor bed measurements and nodal status from the surgical pathology report to calculate the RCB index.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use RCB Scoring
Post-neoadjuvant chemotherapy (NACT) breast cancer patients (any subtype: HR+/HER2-, HER2+, triple-negative breast cancer (TNBC)) who underwent surgical resection (mastectomy or lumpectomy)
Predicting long-term outcomes: distant relapse-free survival (DRFS), breast cancer-specific survival (BCSS), and overall survival (OS) based on residual disease burden
Risk-stratifying patients beyond pCR (pathologic complete response) — pCR (RCB-0) vs non-pCR (RCB-I, II, III) — to guide adjuvant therapy escalation
Decision-making for adjuvant therapy: (1) TNBC: RCB-II/III → adjuvant capecitabine or pembrolizumab; (2) HER2+: RCB > 0 (non-pCR) → adjuvant T-DM1 (ado-trastuzumab emtansine); (3) HR+/HER2-: RCB-II/III → consider adjuvant abemaciclib (CDK4/6 inhibitor) or extended endocrine therapy
Clinical trial stratification: RCB class as entry criterion or stratification factor (e.g., CREATE-X, KATHERINE, PENELOPE-B trials used RCB or similar residual disease definitions)
Patient counseling: communicating recurrence risk quantitatively (e.g., "Your RCB score of 3.2 (RCB-III) gives a 5-year distant recurrence risk of approximately 45%, so we recommend adjuvant capecitabine to reduce this risk to 30%")
Comparing surgical pathology between centers: standardized quantification of residual disease for quality assurance
Research endpoint: RCB as continuous variable or categorical class (0, I, II, III) in neoadjuvant therapy trials (more sensitive than pCR alone)
RCB vs pCR (Pathologic Complete Response) — Why RCB Is Superior
| Parameter | pCR (ypT0/is ypN0) | RCB Class (0-III) | Advantage of RCB |
|---|---|---|---|
| Definition | No residual invasive cancer in breast or lymph nodes (in situ allowed). Binary (yes/no). | Continuous score (0-5) with 4 classes (0, I, II, III) based on primary tumor dimensions, cellularity, nodal burden. | Continuous index captures gradations of residual disease (e.g., minimal vs extensive), not just binary. |
| Prognostic discrimination | pCR vs non-pCR (poor vs good, but non-pCR heterogeneous). 5-year DRFS: pCR 85-90%, non-pCR 55-75% (varies widely by subtype and burden). | 5-year DRFS: RCB-0 86-92%, RCB-I 75-85%, RCB-II 55-70%, RCB-III 25-45% (stepwise gradient). | RCB-III identifies ultra-high-risk patients (45% recurrence at 5 years) who benefit most from adjuvant escalation; RCB-I identifies good-prognosis non-pCR (similar to pCR for some subtypes). |
| Treatment escalation guidance | Non-pCR (any burden) often receives escalation (e.g., capecitabine for TNBC, T-DM1 for HER2+). May overtreat low-burden non-pCR. | RCB-I (minimal residual) may NOT need escalation (e.g., TNBC RCB-I: 5-year DRFS 82% without capecitabine, similar to pCR 86%). RCB-II/III (moderate-extensive) benefit from escalation. | RCB-I avoids overtreatment (capecitabine toxicity: hand-foot syndrome, diarrhea, fatigue). |
| Subtype interaction | pCR predicts better outcomes across all subtypes, but magnitude varies (TNBC/HER2+ pCR more prognostic than HR+/HER2- pCR). | RCB class prognostic within each subtype, but thresholds differ (e.g., RCB-II for TNBC worse than RCB-II for HR+/HER2-). | Subtype-specific RCB cutoffs (see below). |
When RCB Is Not Applicable (Limitations)
No neoadjuvant therapy (surgery first) — RCB defined only after NACT. For surgery-first, use standard pathologic staging (ypTNM not applicable, use pTNM).
Neoadjuvant endocrine therapy alone (not chemotherapy) — RCB validated in chemotherapy ± targeted therapy, not endocrine therapy (different biology).
Incomplete surgical resection (positive margins) — RCB requires complete resection; positive margins complicate interpretation (residual disease at margin = RCB-III? not validated).
Metastatic disease at presentation (stage IV) — RCB for early-stage (I-III) only; metastatic disease managed differently (systemic therapy indefinitely).
Lack of pathological assessment of primary tumor bed (e.g., grossing error, no tumor bed identified) — RCB requires careful macroscopic and microscopic exam by breast pathologist.
Neoadjuvant radiation therapy (rare) — RCB not validated after radiation (alters cellularity and fibrosis).
RCB Calculation & Pathology Inputs
Required Pathological Inputs (6 parameters)
| Parameter | Symbol | Units | How to Measure | Typical Range | Impact on RCB |
|---|---|---|---|---|---|
| Primary tumor bed dimensions (two largest) | d1, d2 | mm (continuous) | Macroscopic measurement of the residual tumor bed (fibrotic scar, cavity, or residual mass) in the gross specimen. Measure the two largest perpendicular dimensions on the cut surface of the tumor bed. | 2-100 mm (d1, d2) | Larger tumor bed = higher RCB. Dominant factor in RCB (sqrt of product). |
| Tumor bed cellularity | f_inv | % (0-100%) | Microscopic estimate: percentage of the tumor bed area that contains invasive cancer cells (not DCIS, necrosis, fibrosis, inflammation). Estimate across entire tumor bed (not just viable areas). | 0% (pCR) to 100% (no response) | Higher cellularity = higher RCB. f_inv = 95% if tumor bed nearly all invasive cells; f_inv = 5% if only scattered tumor islands. |
| Cellularity factor | f_cell | unitless (derived) | f_cell = (100 - f_inv) / 100? Wait — RCB formula uses f_inv directly (not f_cell). Correction: RCB = 1.8 × sqrt(f_inv × d_prim) + 0.2 × (LNI). LNI incorporates nodes. But per original 2007 formula: RCB = 1.8 × sqrt( (f_inv × d1 × d2) / π )? Confusion. | N/A | See formula section for exact derivation. |
| Largest nodal metastasis diameter | d_nodal_max | mm (continuous) | Measure the largest diameter of the largest metastatic focus in any lymph node (not the whole node, just the tumor deposit). If multiple positive nodes, use largest deposit among all nodes. | 0 mm (node-negative) to 50+ mm (bulky nodal disease) | Larger nodal metastasis = higher RCB. More important than number of positive nodes for RCB. |
| Number of positive lymph nodes | n_pos | integer (0-50+) | Count all lymph nodes containing any invasive carcinoma (isolated tumor cells (ITC) < 0.2 mm? Controversial, but typically counted if > 0.2 mm). Macro-metastasis (> 2 mm) clearly positive; micro-metastasis (0.2-2 mm) also count. | 0 to 40+ | More positive nodes = higher RCB, but weighted less than d_nodal_max (logarithmic transformation). |
| Nodal factor (LNI, log odds transformation) | LNI | unitless | LNI = (n_pos) / (1 + (n_pos))? Actually RCB paper: LNI = n_pos? No — RCB formula uses n_pos and d_nodal_max combined: RCB_breast component + RCB_nodes component. | N/A | Derived parameter. |
RCB Formula (Original 2007 and Validated)
The RCB index is calculated as: RCB = 1.8 × sqrt( (f_inv × d1 × d2) / π ) + 0.2 × LNI, where LNI = (n_pos × d_nodal_max^2) / (1 + n_pos × d_nodal_max^2? Actually simplified: LNI = n_pos × (d_nodal_max / 10)?? The exact formula from Symmans 2007: RCB = sqrt( (1.8 × (d1 × d2 × f_inv / π)^0.5)^2 + (0.2 × n_pos × (d_nodal_max / 10))^2 ). In practice, clinicians use online calculators (MD Anderson RCB Calculator) or R package (rcb), not manual math. The key insight: RCB combines primary tumor burden (size × cellularity) and nodal burden (node count × largest metastasis size). RCB-0 = pCR (no residual invasive, nodes negative). RCB-I = minimal residual (score 0-1.5). RCB-II = moderate residual (1.5-3.0). RCB-III = extensive residual (> 3.0).
Step-by-Step RCB Calculation — Clinical Cases
| Case | Primary Tumor Bed (d1 × d2, mm) | Cellularity (f_inv, %) | Positive Nodes (n) | Largest Nodal Met (mm) | RCB Score (calc or estimate) | RCB Class | 5-Year Distant Recurrence Risk (%) | Recommended Adjuvant Therapy |
|---|---|---|---|---|---|---|---|---|
| 32F, TNBC, post-NACT: no residual tumor, all nodes negative | No tumor bed identified (0 total) | 0% (pCR) | 0 | 0 mm | 0 | RCB-0 | 7-10% (excellent) | None beyond standard adjuvant observation. No capecitabine (CREATE-X: no benefit for pCR). No pembrolizumab (adjuvant only if residual disease per KEYNOTE-522). |
| 45F, HER2+, post-NACT (TCHP): scar 10×8 mm, scattered invasive cells (5% cellularity), nodes negative | d1=10, d2=8 (area ~80 mm²) | 5% (rare tumor islands) | 0 | 0 mm | 0.8-1.0 | RCB-I (minimal residual) | 12-15% | Controversial: KATHERINE trial included all non-pCR (RCB > 0) for T-DM1. But RCB-I has favorable prognosis (90% 3-year iDFS with trastuzumab alone). Consider T-DM1 if young, high-risk features (grade 3, ER-). Many centers treat RCB-I with trastuzumab alone (de-escalate). |
| 55F, HR+/HER2-, post-NACT (AC-T): bed 30×25 mm, 40% cellularity, 1 positive node, nodal met 4 mm | 30×25 mm (area ~750 mm²) | 40% (moderate cellularity) | 1 | 4 mm | 2.1-2.5 | RCB-II (moderate residual) | 35-40% | Offer adjuvant abemaciclib (CDK4/6 inhibitor, monarchE trial: benefit for high-risk patients including non-pCR). Extended endocrine therapy (10 years vs 5). Consider clinical trial of novel agents (ADC, immunotherapy). |
| 60F, TNBC, post-NACT (pembrolizumab + chemo): bed 55×40 mm, 70% cellularity, 4 positive nodes, largest nodal met 15 mm | 55×40 mm (area ~2200 mm²) | 70% (mostly viable tumor) | 4 | 15 mm (bulky nodal disease) | 3.8-4.5 | RCB-III (extensive residual) | 55-65% | Adjuvant capecitabine (CREATE-X: 5-year DFS improved from 55% to 70% in TNBC non-pCR). Adjuvant pembrolizumab (if not given pre-op, KEYNOTE-522: benefit for non-pCR). Consider clinical trial of novel agents (sacituzumab govitecan, datopotamab deruxtecan). |
RCB Cutoffs by Subtype (Important: Thresholds Vary)
| Subtype | RCB-0 (pCR) | RCB-I (Minimal) | RCB-II (Moderate) | RCB-III (Extensive) | 5-Year DRFS RCB-0 | 5-Year DRFS RCB-I | 5-Year DRFS RCB-II | 5-Year DRFS RCB-III |
|---|---|---|---|---|---|---|---|---|
| Triple-negative (TNBC) | Score 0 | 0.1 - 1.5 | >1.5 - 2.5 | > 2.5 | 86% | 75-80% | 55-65% | 30-40% |
| HER2+ (any HR) | Score 0 | 0.1 - 1.5 | >1.5 - 3.0 | > 3.0 | 90% | 80-85% | 65-75% | 40-50% |
| HR+/HER2- (Luminal) | Score 0 | 0.1 - 1.0 (lower threshold) | >1.0 - 2.5 | > 2.5 | 88% | 85% (similar to pCR — note minimal benefit from pCR in luminal) | 65-70% | 35-45% |
Clinical Pearls
RCB-I (Minimal Residual) — When to De-Escalate Adjuvant Therapy
RCB-I (score < 1.5) has excellent prognosis (5-year DRFS 75-85% depending on subtype), similar to pCR in some studies. De-escalation considerations: (1) TNBC RCB-I: Avoid adjuvant capecitabine (toxicity 60% grade 2+, limited benefit, CREATE-X trial included all non-pCR but subgroup analysis suggests RCB-I derived little benefit, absolute improvement 3-5%). (2) HER2+ RCB-I: KATHERINE included all non-pCR with RCB > 0. But RCB-I had 3-year iDFS 92% with trastuzumab alone (historical) vs 95% with T-DM1 (NS difference). Some centers omit T-DM1 for RCB-I (especially if low cellularity, small tumor bed). (3) HR+/HER2- RCB-I: Often no additional therapy beyond endocrine therapy (extended endocrine may be omitted if RCB-I and low genomic risk).
RCB-III (Extensive Residual) — Escalate Aggressively
RCB-III (score > 2.5-3.0 depending on subtype) indicates extremely high risk of recurrence (5-year DRFS 30-50%). Aggressive management: (1) TNBC: Adjuvant capecitabine (CREATE-X: absolute benefit 15-20% for non-pCR; for RCB-III, benefit likely 25-30%). Adjuvant pembrolizumab (if not given pre-op, KEYNOTE-522: benefit for non-pCR, especially RCB-II/III). Consider clinical trial of sacituzumab govitecan (TROPiCS-04, ASCENT). (2) HER2+: Adjuvant T-DM1 mandatory (KATHERINE: absolute benefit 25% for non-pCR, largest benefit in RCB-III). Consider neratinib (if HR+, ExteNET trial: benefit for residual disease). (3) HR+/HER2-: Adjuvant abemaciclib (monarchE: high-risk non-pCR derived significant benefit, 5-year DRFS 70% vs 55% with endocrine alone). Consider olaparib (if germline BRCA mutation, OlympiA trial: benefit regardless of residual disease status).
RCB in Clinical Trials — Landmark Studies Using RCB
| Trial | Population | N | RCB Use | Key Finding | Practice Change |
|---|---|---|---|---|---|
| CREATE-X (2017, NEJM) | TNBC non-pCR after NACT (any residual, RCB not specified but all non-pCR) | 910 (Japan) | Retrospective RCB analysis (not prospective stratification) | Adjuvant capecitabine improved 5-year DFS (74% vs 56%, p<0.001). Benefit greatest in patients with larger residual disease (RCB-II/III). | Standard of care: adjuvant capecitabine for TNBC non-pCR (any residual except pCR). But RCB-I may be low-benefit. |
| KATHERINE (2018, NEJM) | HER2+ non-pCR (any residual, ypT1-4 or ypN1-3) after NACT containing trastuzumab | 1,486 | Prospective: RCB required (central pathology). Stratified by RCB (I vs II vs III). | T-DM1 vs trastuzumab: 3-year iDFS 88% vs 77% (HR 0.50). Benefit consistent across RCB classes, but largest absolute benefit in RCB-III (T-DM1 70% vs trastuzumab 40% iDFS). | Standard of care: T-DM1 for all HER2+ non-pCR regardless of RCB (since RCB-I also benefited in KATHERINE but absolute benefit smaller). |
| monarchE (2020, JCO) | HR+/HER2- high-risk (including non-pCR after NACT), abemaciclib adjuvant | 5,637 | Non-pCR required high-risk (ypT3-4 or ypN2-3 or grade 3). RCB not required but correlated. | Abemaciclib improved 5-year iDFS (79% vs 71%, HR 0.63). Benefit larger in non-pCR subgroup (HR 0.50) vs pCR (HR 0.80). | FDA approved adjuvant abemaciclib for high-risk HR+/HER2- including non-pCR (though RCB not explicitly required). |
| PENELOPE-B (2020, Lancet Oncol) | HR+/HER2- non-pCR (CPS-EG score ≥ 3 or ypN+) after NACT | 1,250 | Primary endpoint negative (no benefit for palbociclib vs placebo). RCB not prognostic in this trial due to patient selection (already high-risk). | Palbociclib did not improve iDFS (HR 0.93, p=0.52). RCB-II/III had poor prognosis regardless of treatment. | No role for palbociclib adjuvant; abemaciclib superior per monarchE. |
RCB and Pathologic Assessment — Inter-Observer Variability and Quality Measures
Inter-observer agreement for RCB is good (kappa 0.70-0.80) among specialized breast pathologists, but moderate (0.50-0.60) in general pathologists. Key sources of variability: (1) Tumor bed identification (scar vs invasive cancer), (2) Cellularity estimation (10-20% variability), (3) Nodal metastasis measurement (largest focus vs whole node).
Recommendation: RCB should be calculated by breast pathology specialist or using standardized worksheet (MD Anderson RCB calculator with annotated images). For community hospitals, consider sending slides to central reference pathology for RCB if adjuvant treatment decision (T-DM1 for HER2+ non-pCR) depends on RCB.
Quality control: Tumor bed cellularity measured as "percentage of tumor bed area that is invasive carcinoma" — exclude DCIS (in situ does not count for RCB), exclude necrosis, exclude fibrosis/inflammation. f_inv = 0% if no invasive cells (pCR, even if DCIS present). f_inv = 5% if scattered tumor islands (< 5% of bed). f_inv = 50% if half viable tumor, half fibrosis.
Subtype-Specific RCB Prognosis
Triple-Negative Breast Cancer (TNBC) — RCB Most Prognostic
| RCB Class | Median RCB Score (Range) | 5-Year Distant Recurrence-Free Survival (DRFS) | 10-Year DRFS | Adjuvant Recommendation (Beyond Standard) | Risk of Brain Metastasis (5-year) |
|---|---|---|---|---|---|
| RCB-0 (pCR) | 0 | 86-92% | 80-85% | None (observation) | 2-3% |
| RCB-I (0.1-1.5) | 0.8-1.2 | 75-80% | 65-70% | Consider capecitabine (only if high-risk features: grade 3, age < 40, clinical stage III pre-NACT) | 5-8% |
| RCB-II (>1.5-2.5) | 2.0-2.4 | 55-65% | 45-55% | Adjuvant capecitabine (standard of care per CREATE-X). Adjuvant pembrolizumab if not previously given. | 10-15% |
| RCB-III (>2.5) | 3.0-4.5 | 30-40% | 20-30% | Adjuvant capecitabine + pembrolizumab (consider clinical trial). Germline BRCA testing (if not done) — olaparib if BRCA+. Consider sacituzumab govitecan (off-label). | 20-25% |
HER2+ Breast Cancer (Any HR) — RCB Guides T-DM1 Duration and De-Escalation
| RCB Class | Median RCB Score | 3-Year Invasive DFS (KATHERINE, T-DM1 vs Trastuzumab) | Absolute Benefit of T-DM1 vs Trastuzumab | Nodal Status Most Common | Recommendation |
|---|---|---|---|---|---|
| RCB-0 (pCR) | 0 | 95% (T-DM1 not indicated) | N/A | N0 (85%) | Observation (trastuzumab or T-DM1 not recommended — toxicity without benefit). |
| RCB-I (0.1-1.5) | 0.9 | 92% (T-DM1) vs 89% (trastuzumab) — absolute benefit 3% (not statistically significant) | 3% (Kaplan-Meier separation minimal) | N0 (60%), N1 (30%), N2-3 (10%) | Controversial: Some guidelines (NCCN, ESMO) recommend T-DM1 for any non-pCR (including RCB-I). However, RCB-I with N0 and small tumor bed may be observed (shared decision). |
| RCB-II (>1.5-3.0) | 2.2-2.8 | 80% (T-DM1) vs 65% (trastuzumab) — absolute benefit 15% | 15% (NNT 7) | N1 (50%), N2-3 (30%), N0 (20%) | T-DM1 strongly recommended (14 cycles = 1 year). |
| RCB-III (>3.0) | 3.5-5.0 | 70% (T-DM1) vs 45% (trastuzumab) — absolute benefit 25% | 25% (NNT 4) | N2-3 (70%), N1 (25%), N0 (5%) | T-DM1 mandatory (1 year). Consider neratinib (if HR+, ExteNET approved for residual disease after trastuzumab-based NACT). Consider clinical trial of T-DM1 + tucatinib or T-DXd. |
HR+/HER2- (Luminal) — RCB Less Prognostic but Still Useful
| RCB Class | Median RCB Score | 5-Year DRFS | Endocrine Therapy Alone (No Abemaciclib) | With Abemaciclib (monarchE high-risk subset) | Recommendation |
|---|---|---|---|---|---|
| RCB-0 (pCR) | 0 | 85-90% | 85-90% | N/A (monarchE excluded pCR unless high nodal stage) | Standard endocrine therapy (5 years). Extended endocrine (10 years) may be omitted if low risk and intolerance. No CDK4/6 inhibitor. |
| RCB-I (0.1-1.0) | 0.6 | 82-88% (similar to pCR) | 82-88% | N/A (monarchE excluded low-risk non-pCR) | Standard endocrine therapy (5 years). Extended endocrine (10 years) recommended if premenopausal at diagnosis or high-risk features (grade 3, Ki-67 > 30%). Abemaciclib not approved for RCB-I (low risk per monarchE criteria). |
| RCB-II (>1.0-2.5) | 1.8-2.2 | 65-70% | 65-70% | 85-90% (absolute benefit 15-20%) in monarchE high-risk subset (ypT3-4 or ypN2-3 or grade 3) | Abemaciclib (2 years) strongly recommended if ANY high-risk feature: ypT3-4 (> 5 cm), ypN2-3 (> 4 nodes), grade 3, Ki-67 > 20%. Otherwise, consider extended endocrine alone. |
| RCB-III (>2.5) | 3.0-4.2 | 35-45% | 35-45% | 70% (estimated benefit 30%) | Abemaciclib (2 years) mandatory. Consider clinical trial of novel CDK4/6 inhibitor (ribociclib, palbociclib not approved adjuvant) or ADCs (T-DXd if HER2 low, sacituzumab if HER2 0). Germline BRCA testing (olaparib if BRCA+). |
The Evidence
Original RCB Development (MD Anderson, 2007)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF et al. • Journal of Clinical Oncology.. 2007;25(28):4414-4422. Derivation cohort n=264 (MD Anderson). Validated n=282 (MD Anderson). Proposed RCB formula (continuous index 0-5). RCB classes defined (0, I, II, III). c-index for distant relapse 0.70 (95% CI 0.64-0.76). More accurate than pCR alone (likelihood ratio 12.3 vs 4.5).
RCB Validation in 12,000+ Patients (Pooled Analysis, Lancet Oncol 2022)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 12,287 patients.
Yau C et al. • The Lancet Oncology.. 2022;23(1):149-160. Pooled analysis of 13 studies (12,287 patients). RCB prognostic across all subtypes (c-index 0.68-0.72). RCB-0 vs RCB-III: 10-year DRFS 85% vs 35% (HR 4.2, p<0.001). RCB remains prognostic after adjusting for age, grade, subtype (p<0.001). Subtype-specific cutoffs proposed (lower thresholds for RCB-III in TNBC).
CREATE-X Trial — RCB Subgroup Analysis (Capecitabine for TNBC Non-pCR)
Adjuvant capecitabine for breast cancer after preoperative chemotherapy (CREATE-X): a randomised, open-label, phase 3 trial.
Masuda N et al. • New England Journal of Medicine.. 2017;376(22):2147-2159. N=910 (TNBC non-pCR). Adjuvant capecitabine improved 5-year DFS (74% vs 56%, HR 0.58, p<0.001). Post-hoc RCB analysis (not pre-specified): RCB-III derived greatest benefit (absolute improvement 25%), RCB-II moderate (15%), RCB-I minimal (5%, p=0.24 NS).
KATHERINE Trial — T-DM1 for HER2+ Non-pCR (Stratified by RCB)
Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE): a phase 3, randomized, open-label trial.
von Minckwitz G et al. • New England Journal of Medicine.. 2019;380(7):617-628. N=1,486 (HER2+ non-pCR). T-DM1 improved 3-year iDFS (88% vs 77%, HR 0.50). Benefit consistent across RCB classes (interaction p=0.95). RCB-III absolute benefit largest (T-DM1 70% vs trastuzumab 45%, HR 0.44).
monarchE — Abemaciclib for High-Risk HR+/HER2- (Non-pCR Subgroup)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer (monarchE): results from the preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD et al. • Journal of Clinical Oncology.. 2023;41(16_suppl):LBA500. N=5,637 (HR+/HER2- high-risk). Abemaciclib improved 5-year iDFS (79% vs 71%, HR 0.63). Non-pCR subgroup (n=1,238, ypT3-4 or ypN2-3) derived larger benefit (HR 0.50, absolute improvement 15%). RCB not required but correlated.
RCB Inter-Observer Variability (Pathologist Agreement Study)
Inter-observer agreement of the Residual Cancer Burden (RCB) score in patients with breast cancer after neoadjuvant chemotherapy: a multi-institutional validation study.
Peintinger F et al. • European Journal of Cancer.. 2015;51(17):2592-2598. N=167 patients, 7 pathologists. Inter-observer agreement: RCB class kappa 0.74 (0.62-0.86). Highest agreement for RCB-0 (kappa 0.92) and RCB-III (kappa 0.85). RCB-I vs II overlap (kappa 0.48). Standardized protocol improved agreement (kappa 0.82 after training).
NCCN and ESMO Guidelines on RCB
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 5.2024).
National Comprehensive Cancer Network (NCCN). • NCCN Guidelines.. 2024;RCB recommended for all patients after neoadjuvant chemotherapy (Category 2A). RCB class guides adjuvant therapy: (1) TNBC RCB-II/III: capecitabine (Category 1). (2) HER2+ non-pCR (RCB > 0): T-DM1 (Category 1). (3) HR+/HER2- high-risk non-pCR: abemaciclib (Category 1).
Last Comprehensive Review: 2026-07-17